Replimune Group (NASDAQ:REPL) Stock Price Down 5.2% - Here's What Happened

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report)'s stock price traded down 5.2% during mid-day trading on Monday . The stock traded as low as $10.75 and last traded at $10.88. 262,254 shares changed hands during trading, a decline of 76% from the average session volume of 1,103,334 shares. The stock had previously closed at $11.48.

Wall Street Analyst Weigh In

REPL has been the topic of a number of recent analyst reports. HC Wainwright reiterated a "buy" rating and issued a $17.00 price objective on shares of Replimune Group in a research report on Monday, September 16th. JPMorgan Chase & Co. increased their price objective on Replimune Group from $14.00 to $17.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 24th. Roth Mkm initiated coverage on Replimune Group in a research report on Tuesday, August 27th. They issued a "buy" rating and a $17.00 price objective on the stock. Finally, Roth Capital upgraded Replimune Group to a "strong-buy" rating in a research report on Tuesday, August 27th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $16.80.

Replimune Group Trading Down 7.1 %

The firm has a market cap of $655.30 million, a P/E ratio of -3.45 and a beta of 1.21. The company has a debt-to-equity ratio of 0.16, a current ratio of 13.46 and a quick ratio of 13.46. The stock has a 50 day moving average of $10.62 and a 200 day moving average of $8.74.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.78) EPS for the quarter, beating analysts' consensus estimates of ($0.88) by $0.10. As a group, equities research analysts predict that Replimune Group, Inc. will post -3.11 EPS for the current year.

Insider Activity at Replimune Group

In other news, CFO Emily Luisa Hill sold 8,938 shares of the firm's stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the transaction, the chief financial officer now directly owns 101,057 shares of the company's stock, valued at approximately $1,028,760.26. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 20.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of REPL. Millennium Management LLC grew its stake in shares of Replimune Group by 575.1% during the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company's stock valued at $28,062,000 after buying an additional 2,656,173 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Replimune Group by 300.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,238,883 shares of the company's stock worth $18,874,000 after purchasing an additional 1,679,553 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Replimune Group by 12.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company's stock worth $53,505,000 after purchasing an additional 699,679 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Replimune Group during the first quarter worth about $1,088,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of Replimune Group during the first quarter worth about $927,000. 92.53% of the stock is owned by institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.